High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

PURPOSE: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatini...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Cortes, Jorge E., Kantarjian, Hagop M., Goldberg, Stuart L., Powell, Bayard L., Giles, Francis J., Wetzler, Meir, Akard, Luke, Burke, John M., Kerr, Robert, Saleh, Mansoor, Salvado, August, McDougall, Karen, Albitar, Maher, Radich, Jerald
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979200/
https://ncbi.nlm.nih.gov/pubmed/19720924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.3869
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars